Press Releases from Crucell N.V. (7 total)
direct/ Crucell N.V. (NL) - CRUCELL AND BERNA BIOTECH: TOGETHER CREATING THE LE …
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA
This announcement and related materials do not constitute an offer for Berna shares. An offer is expected to be made in due course as set out in this press release.
Furthermore, this press release is not a pre-announcement within the meaning of Swiss takeover laws, is not binding and…
Crucell N.V. (NL) - Crucell and DSM Announce PER.C6® Licensing Agreement with …
Crucell and DSM Announce PER.C6® Licensing Agreement with IQ Corporation for Production of Monoclonal Antibodies against Anthrax
Leiden/Sittard, The Netherlands, October 19, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with Dutch biotechnology company IQ Corporation. This license agreement allows IQ to evaluate and use the PER.C6® cell line for production…
Crucell N.V. (NL) - Crucell Announces Third Quarter 2005 Results
Crucell Announces Third Quarter 2005 Results
- Strong increase in quarter and year-to-date revenues.
- New development programs in rabies and tuberculosis.
- Further AdVac®-based vaccine technology development contracts with US partners.
- Initiated therapeutic protein programs.
Leiden, The Netherlands, October 17, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) today announced its financial results for the third quarter and for the nine months ended September 30, 2005.
Revenue…
Crucell N.V. (NL) - Crucell Updates Progress in Scale-up of Cell-culture-based I …
Crucell Updates Progress in Scale-up of Cell-culture-based Influenza Vaccine Programs
Leiden, The Netherlands, October 13, 2005 - Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has received a milestone payment of EUR 1 million (US$ 1.2 million) from sanofi pasteur, the vaccines business of the sanofi-aventis group, in acknowledgement of the progress the company has made in development of novel influenza products using Crucell´s proprietary PER.C6® cell line technology. The…
Crucell N.V. (NL) - Merck and Co., Inc. Exercises Option on PER.C6® License for …
Merck and Co., Inc. Exercises Option on PER.C6® License for Adenovirus-based Vaccine Against Hepatitis C
Leiden, The Netherlands, October 10, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that Merck & Co., Inc. (NYSE: MRK) has exercised its option to use Crucell´s PER.C6® production technology to develop an adenovirus-based vaccine against hepatitis C (HCV). Crucell will receive a US$ 1 million (EURO 0.8 million) exercise fee with…
Crucell N.V. (NL) - Crucell Secures EUR 2 Million Grant from Dutch Ministry of …
Crucell Secures EUR 2 Million Grant from Dutch Ministry of Economic Affairs to Discover Antibodies Against Antibiotic-resistant Bacterial Infections
Leiden, The Netherlands, September 16, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has received a grant of up to EUR 2 Million from the SenterNovem Innovation Subsidy for Collaborative Projects program of the Dutch Ministry of Economic Affairs. The grant supports a collaborative effort aimed…
Crucell N.V. (NL) - Crucell and Aeras Announce Progress in TB Vaccine Program
Crucell and Aeras Announce Progress in TB Vaccine Program
Leiden, The Netherlands, September 8, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and Aeras Global TB Vaccine Foundation today announced the initiation of a series of clinical studies for their AdVac®-based TB vaccine. The studies, which follow promising results for the vaccine obtained in animal studies, are scheduled to start in Europe, the US and Africa in the…
